Anti-P53 single-chain antibody fragments and their uses

Details Anti-P53 single-chain antibody fragments and their uses Anti-P53 single-chain antibody fragments and their uses

2005-02-08

2005-02-08

Fredman, Jeffrey (Department: 1636)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S320100, C435S325000, C435S455000, C530S350000, C530S387100, C530S389100, C530S389200, C536S023100, C536S023500

Reexamination Certificate

active

06852509

ABSTRACT:
The invention concerns single-chain antibodies directed against the p53 protein, capable of being expressed in tumoral cells, capable of restoring a DNA binding in vitro and a transcription activator function in vivo. The invention also concerns nucleic acids coding for these molecules, the vectors containing them and their uses.

REFERENCES:
patent: WO 9412202 (1994-06-01), None
patent: WO 9630512 (1996-10-01), None
patent: WO 9704092 (1997-02-01), None
Herbert et al. The Dictionary of Immunology, Academic Press, 4th edition, 1995).*
Greenspan et al, Definig epitopes: It's not easy as it semms. Nature Biotechnology 7:936-937, 1999.*
Legros et al Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. Oncogene 9:3689-3694, 1994.*
Caron de Fromentel et al Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 18(2):551-7, 1999.*
Rosenberg et al., Gene therapist, heal thyself, 2000, SCIENCE, vol. 287 p. 1751.*
Verma, Gene therapy beyond 2000, 2000, Molecular Therapy, vol. 1 No. 6 p. 493.*
Friedmann, Principles for human gene therapy studies, 2000, SCIENCE, vol. 287, pp. 2163-2164.*
Anderson, Human gene therapy, 1998, NATURE, vol. 392, pp. 25-30.*
Verma et al., Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389, pp. 239-242.*
Jannot et al., Characterization of scFv-421, a single-chain antibody targeted to p53, 1997, Biochemical and Biophysical Research Communications, vol. 230, pp. 242-246.*
Hupp et al., Strategies for manipulating the p53 pathway in the treatment of human cancer, 2000, Biochemistry Journal, vol. 352 pp. 1-17.*
Mastrangelo et al., Gene therapy for human cancer: An essay for clinicians, 1996, Seminars in Oncology, vol. 23 No. 1 pp. 4-21.*
Gomez-Navarro et al., Gene therapy for cancer, 1999, European Journal of Cancer, vol. 35 No. 6 pp. 867-885.*
Kelloff et al., Cancer chemoprevention: progress and promise, 1999, European Journal of Cancer, vol. 35 No. 14 pp. 2031-2038.*
Varmus, Gene therapy: Not ready for prime time, 1996, Nature Medicine, vol. 2 No. 1 pp. 7-8.*
Abarzua et al., Microinjection of Monoclonal Antibody PAb421 Into Human SW480 Colorectal Carcinoma Cells Restores the Trascription Activation Function To Mutant p53, Cancer Research 55, 3490-3494 (1995).
Hupp et al., Regulation of the Specific DNA Binding Function of p53, Cell, 71, 875-886 (1992).
Halazonetis et al., Wild-type p53 adopts a ‘mutant’-like conformation when bound to DNA, The EMBO Journal 12(3), 1021-1028 (1993).
Jannot et al., Characterization of scFv-421, a Single-Chain Antibody Targeted to p53, Biochemical & Biophysical Research Comm., 230, 242-246 (1997).

Affiliated with

Also associated with

Rating

Anti-P53 single-chain antibody fragments and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-P53 single-chain antibody fragments and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-P53 single-chain antibody fragments and their uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3506609